The research team, led by Yamin Li and colleagues, analyzed 615 patients with pathologically confirmed papillary thyroid carcinoma who underwent total or near-total thyroidectomy with lymph node dissection followed by their first course of radioactive iodine ablation. The cohort included 189 men and 426 women ranging from 16 to 80 years of age, with a mean age of about 42 years. Using the 2025 American Thyroid Association recurrence-risk framework, the investigators re-stratified the patients into low/low-to-intermediate and intermediate-high/high risk categories, deliberately excluding anyone with distant metastases at baseline so that “high risk” in this cohort reflected only loco-regional disease features such as gross extrathyroidal extension, extranodal extension, bulky nodal disease, or aggressive histology.

Treatment response was assessed six months after iodine-131 therapy, a time point consistent with the ATA’s dynamic risk assessment system, using suppressed thyroglobulin, thyroglobulin antibody levels, diagnostic whole-body scintigraphy, and SPECT/CT imaging. Patients were classified into four categories: excellent response, indeterminate response, biochemical incomplete response, and structural incomplete response—the latter defined by suspicious imaging findings or biopsy-proven local or distant metastatic disease. For analytical purposes, the first three categories were grouped together as non-SIR. The contrast between risk strata was striking: structural incomplete response occurred in just 10.4 percent of low/low-to-intermediate risk patients but in 38.1 percent of the intermediate-high/high risk group, a difference the authors describe as highly statistically significant.

Digging deeper into each stratum, the researchers found that the determinants of treatment failure differed markedly depending on baseline risk. In the lower-risk group, univariate analysis flagged stimulated thyroglobulin, the presence of lymph node metastasis, thyroglobulin antibody levels, and the administered iodine-131 dose as significant factors, while gender, T stage, the number of lymph nodes removed, the lymph node ratio, and age showed no association. Receiver operating characteristic analysis identified optimal predictive cutoffs of 1.5 ng/mL for stimulated thyroglobulin and more than 2.5 metastatic nodes, and combining the two variables pushed the area under the curve to 0.768. Multivariable analysis in this group ultimately retained stimulated thyroglobulin, thyroglobulin antibody, and iodine-131 activity as factors associated with structural incomplete response.

The intermediate-high/high risk group told a different story. Here, stimulated thyroglobulin, the number of metastatic lymph nodes, the total number of nodes removed, the lymph node ratio, thyroglobulin antibody, and treatment dose all reached statistical significance on univariate testing. ROC-derived cutoffs were 11.625 ng/mL for stimulated thyroglobulin and 11.5 metastatic nodes, with the combination achieving an area under the curve of 0.786. Multivariable logistic regression distilled these down to three independent predictors: stimulated thyroglobulin, the number of metastatic lymph nodes, and the total number of nodes examined. Notably, each additional metastatic node raised the odds of structural incomplete response by 23 percent, while each additional node examined was modestly protective—an effect the authors attribute to more thorough surgical and pathological staging.

The most clinically consequential part of the study, however, focused on the intermediate-risk “grey zone,” the population in which the decision to administer radioactive iodine remains most contested. From 396 intermediate-risk patients—defined as those with recurrence risks between 10 and 30 percent under the 2025 framework—the team randomly partitioned 297 into a training set and 99 into a validation set. Five variables emerged as independent predictors of structural incomplete response in the training cohort: age, tumor size, the number of lymph node metastases, the lymph node ratio, and stimulated thyroglobulin. Each carried a biologically plausible signal. Older patients tend to have reduced radioiodine avidity; larger tumors reflect greater burden; and nodal metrics quantify the extent of metastatic disease.

From these five predictors the investigators constructed a nomogram, a point-based graphical calculator that clinicians can use at the bedside. ROC analysis supplied practical thresholds: more than 8.5 metastatic lymph nodes, stimulated thyroglobulin above 7.46 ng/mL, a lymph node ratio exceeding 0.30, age over 42.5 years, and tumor size greater than 1.05 cm. A physician scores each factor, sums the points, and reads off the patient’s individualized probability of structural incomplete response. In the training cohort the model achieved an area under the curve of 0.865, and bootstrap internal validation with 1,000 resamples and Harrell optimism correction yielded an optimism-corrected C-statistic of 0.853 with a calibration slope of 0.92—evidence of minimal overfitting. Variance inflation factors all fell below 1.1, and the two nodal variables were only weakly correlated, supporting the retention of both.

Discrimination slipped to 0.733 in the held-out validation set, though the authors note the confidence intervals overlap with the training estimate. Decision curve analysis added a further layer of reassurance: across threshold probabilities from 1 to 95 percent, the nomogram’s standardized net benefit exceeded both the treat-all and treat-none strategies, meaning that using the model to guide decisions would, in theory, improve clinical outcomes compared with indiscriminate approaches. Calibration curves in both cohorts showed good agreement between predicted and observed event rates, and the events-per-variable ratio of 12 met accepted standards for logistic regression modeling.

The findings dovetail with a growing body of literature on thyroglobulin dynamics and nodal burden. Prior work has shown that when stimulated thyroglobulin stays below 1 ng/mL, structural incomplete response is essentially never observed; between 1 and 10 ng/mL it occurs in fewer than 2 percent of patients; and above 10 ng/mL the rate climbs to more than 40 percent. Because thyroglobulin is produced only by thyroid tissue and its metastases, rising levels signal residual or recurrent cellular activity. Similarly, the lymph node ratio—positive nodes divided by nodes removed—has repeatedly been linked to poorer disease-specific and overall survival, with a cutoff near 0.3 emerging in earlier studies as prognostically meaningful. The Soochow team’s threshold of 0.30, with 50 percent sensitivity and 93 percent specificity, aligns closely with that precedent.

The authors are candid about the study’s limitations. It was retrospective and single-center, raising the specter of selection bias; the administered iodine-131 activity partly reflects disease severity rather than an independent cause of outcome; dichotomizing continuous predictors discards information; and, crucially, the cohort comprised only patients already selected for radioactive iodine, so the nomogram predicts response within treated patients rather than informing whether therapy should be given at all. External multicenter validation is required before routine clinical use. Still, the contribution is clear: by comparing the determinants of structural incomplete response across ATA risk strata and integrating them into a calibrated, decision-analytically validated tool, the study gives clinicians a way to bring quantitative precision to one of thyroid oncology’s most stubborn gray areas—potentially sparing lower-risk patients unnecessary radiation while intensifying surveillance for those most likely to harbor residual disease.

Subject of Research: Development of a nomogram predicting structural incomplete response to radioactive iodine therapy in intermediate-risk papillary thyroid carcinoma

Article Title: Prognostic Factor Analysis for Risk‐Stratified Papillary Thyroid Carcinoma and Nomogram Development for Predicting Structural Incomplete Response to Radioactive Iodine Therapy in Intermediate‐Risk Patients

Article References: Li, Y., He, Z., Zhao, M., & Zhang, B. (2026). Prognostic Factor Analysis for Risk‐Stratified Papillary Thyroid Carcinoma and Nomogram Development for Predicting Structural Incomplete Response to Radioactive Iodine Therapy in Intermediate‐Risk Patients. Cancer Reports, 9(9), Article e70692. https://doi.org/10.1002/cnr2.70692

Image Credits: AI Generated

DOI: 10.1002/cnr2.70692

Keywords: papillary thyroid carcinoma, radioactive iodine therapy, structural incomplete response, nomogram, thyroglobulin, lymph node metastasis, lymph node ratio, ATA risk stratification, thyroid cancer prognosis, risk prediction model, iodine-131 ablation, decision curve analysis

MROH1, also known as HEATR7A, first drew attention from work on the humble roundworm Caenorhabditis elegans. Researchers had identified the worm protein HPO-27, a HEAT repeat protein, as a critical mediator of lysosomal membrane scission. When HPO-27 is lost, the worm’s tissues fill up with aberrant tubular lysosomal networks instead of the usual discrete vesicles. The mammalian homologue MROH1 was subsequently shown to interact with the WASH–actin machinery to regulate lysosomal fission, positioning it as a gatekeeper of lysosomal integrity. What remained entirely unknown was whether this housekeeping role had any physiological relevance for hormone-producing tissues, and no prior study had ever connected MROH1 to thyroid biology.

A crucial clue came from human gene expression databases. Transcriptomic profiling across the GTEx portal and the Human Protein Atlas classifies MROH1 as markedly tissue-enhanced in the thyroid gland relative to other organs—striking preferential expression for a core component of the lysosomal fission machinery. That observation prompted the Tsukuba team, led by Nami Ohuchi and Yoshinori Osaki under the supervision of Hitoshi Shimano, to generate a global MROH1 knockout mouse line. Sperm carrying the Mroh1(tm1a(KOMP)Wtsi) allele were obtained from the European Mouse Mutant Archive, floxed mice were created by Flpe-mediated excision of the gene trap cassette, and ubiquitous deletion of exons 5 through 7 was achieved by crossing with Ayu1-Cre transgenic mice. Cre-negative floxed littermates served as wild-type controls throughout.

The knockout strategy worked as designed: quantitative RT-PCR confirmed the complete absence of Mroh1 transcripts in the thyroids of the deficient animals. To address possible genetic compensation, the team also measured Mroh2a, a close paralog of Mroh1, and found only a non-significant upward trend in its expression. Metabolic phenotyping then produced a subtle but revealing picture. Food intake and body length were unchanged between genotypes, but the knockout mice gained weight gradually, reaching a statistically significant difference by 24 weeks of age. The weight gain occurred independently of altered skeletal growth, suggesting systemic metabolic adaptations rather than a primary effect on development.

The endocrine phenotype emerged clearly when the researchers measured serum hormones. Free thyroxine (FT4) was significantly reduced in knockout mice at both 3 and 6 months of age, while free triiodothyronine (FT3) was significantly lower by 6 months. Serum TSH showed only a non-significant increasing trend—a puzzling feature the authors openly acknowledge, since standard rodent thyroid economy would predict a compensatory TSH rise when circulating hormones fall. Whether the discrepancy reflects altered central feedback, differences in hormone metabolism, or transport effects remains unresolved and will require functional assessment of the hypothalamic–pituitary axis in future work.

Consistent with the well-known clinical association between hypothyroidism and dyslipidemia, total serum cholesterol was comparable at 3 months but significantly elevated in the knockout animals by 6 months, while triglycerides remained unchanged. Importantly, markers of liver and kidney function, blood glucose, and creatine kinase levels were all unremarkable, and histological examination of the lung, brain, liver, and skeletal muscle revealed no overt abnormalities. The thyroid, in other words, stood out as the principal site of pathological consequence—an outcome that mirrors MROH1’s preferential expression in that gland and strengthens the causal narrative.

To understand the structural basis of the hormone deficit, the team turned to histology. At 3 months of age, thyroid morphology in the knockout mice looked essentially normal. By 6 months, however, the gland showed clear architectural remodelling: follicular area was reduced, and follicles were progressively replaced by interstitial cells and adipocyte-like structures. Quantification of the follicle area ratio showed a downward trend that narrowly missed statistical significance, but a more sensitive analysis of individual follicles—over 1,700 follicles measured across both groups—revealed a statistically significant shift towards smaller follicle sizes in the knockout mice (p = 0.0095, Kolmogorov–Smirnov test). The gland, in effect, was quietly remodelling itself at the cellular level long before gross pathology would appear.

Molecular profiling pointed to the transcriptional roots of the defect. Expression of Nkx2-1 and Foxe1, the master regulators of thyroid differentiation, was significantly reduced in the knockout thyroids, with Pax8 and Hhex trending in the same direction. Concurrently, thyroglobulin—the essential precursor of thyroid hormone synthesis—was significantly downregulated, as was Slc16a2 (Mct8), the thyroid hormone transporter. Other genes involved in hormone production, including Tshr, Slc5a5 (Nis), and Slc26a7, showed decreasing trends. This coordinated loss of lineage-defining transcription factors and their functional target genes suggests that MROH1 is required for the long-term maintenance of follicular cell identity and differentiated function, not merely for organelle housekeeping.

What the study did not find is equally telling. Given MROH1’s established role in lysosomal fission and the dependence of hormone release on lysosomal proteolysis, the team fully expected to find impaired lysosomal function. Instead, immunoblotting showed that protein levels of LAMP2, cathepsin L, and cathepsin D were unchanged, and two independent assays—a live-cell fluorogenic substrate assay in primary thyroid cells and an enzymatic activity assay in whole-tissue lysates—revealed no significant difference in cathepsin L activity. The fundamental capacity for lysosomal degradation appeared intact. The authors caution that bulk assays may simply be too blunt to detect localized defects in lysosomal membrane trafficking, and that subtle, progressive endo-lysosomal trafficking failures could still accumulate over time, as seen in the delayed thyroid pathology of lysosomal storage disease models such as cystinosis.

The broader significance is twofold. First, the work establishes MROH1 as a genetic factor for thyroid hormone homeostasis in vivo, with a phenotype distinct from the profound hypothyroidism and goitre seen in complete MCT8 or thyroglobulin knockouts—the partial downregulation of thyroid genes produces a milder, late-onset endocrine defect without gland enlargement. Second, it extends the emerging view that lysosomal membrane dynamics are not merely cellular plumbing but active participants in tissue-level physiology, with the caveat that the precise mechanistic bridge from MROH1 deficiency to transcriptional downregulation remains to be charted. Because the mice carry a congenital deletion yet show a late-onset phenotype, extrathyroidal contributions cannot be excluded. Tissue-specific knockout models, currently the next step for the Tsukuba group, should disentangle the global versus thyroid-specific roles of MROH1—and may ultimately clarify whether subtle lysosomal trafficking defects in humans contribute to mild hypothyroidism, thyroid remodelling, and the cardiovascular risk that follows from unexplained hypercholesterolemia.

Subject of Research: The role of the HEAT repeat protein MROH1 in lysosomal fission and thyroid hormone homeostasis in mice

Article Title: The HEAT Repeat Protein MROH1 Deficiency Leads to Reduced Circulating Thyroid Hormone Levels in Mice

Article References: Ohuchi, N., Osaki, Y., Nakagawa, Y., Miyamoto, T., Araki, M., Mizunoe, Y., Matsuda, T., Murayama, Y., Sugano, Y., Iwasaki, H., Matsuzaka, T., Sekiya, M., & Shimano, H. (2026). The HEAT Repeat Protein MROH1 Deficiency Leads to Reduced Circulating Thyroid Hormone Levels in Mice. Endocrinology, Diabetes & Metabolism, 9(5), Article e70348. https://doi.org/10.1002/edm2.70348

Image Credits: AI Generated

DOI: 10.1002/edm2.70348

Keywords: MROH1, thyroid hormone, lysosomal fission, hypothyroidism, hypercholesterolemia, knockout mice, Nkx2-1, Foxe1, thyroglobulin, cathepsin L, endocrine physiology, University of Tsukuba

Differentiated high-grade thyroid carcinoma entered the official medical lexicon with the 2022 revision of the World Health Organization classification of thyroid tumors. The category was created to capture a troubling intermediate entity: tumors that retain the recognizable microscopic architecture of differentiated thyroid cancer, the well-behaved papillary and follicular patterns that typically respond well to surgery and radioactive iodine, yet display unmistakable signs of aggressive biological behavior. Under the WHO definition, a differentiated high-grade tumor must show tumor necrosis, meaning patches of dead malignant tissue where the cancer has outgrown its blood supply, or an elevated mitotic count of at least five mitoses per two square millimeters, indicating rapid cellular division. Either finding, layered on top of differentiated morphology, signals a tumor that may behave far worse than its appearance alone would suggest.

The patient in this report arrived with classic compressive symptoms. Dyspnea, or difficulty breathing, and dysphagia, difficulty swallowing, are alarming signs when a neck mass is the culprit, because the thyroid gland sits directly in front of the trachea and esophagus. A six-year history of slow enlargement raises difficult questions about why earlier intervention did not occur, and the case underscores a persistent global problem: slowly growing thyroid masses can be tolerated or overlooked for years until they become bulky, symptomatic, and significantly harder to remove. By the time this patient reached the operating theater, the mass qualified as a giant clinical neck mass, a descriptive term for tumors large enough to distort cervical anatomy and complicate standard surgical technique.

In July 2024, the surgical team performed a total thyroidectomy, the complete removal of the thyroid gland, together with a bilateral central lymph node dissection clearing the compartment behind and beside the thyroid, and a right lateral neck dissection covering lymph node levels II through V. The extent of the operation reflects how thoroughly the disease had spread through the neck’s drainage basins. Pathological examination of the removed tissue confirmed bilateral differentiated high-grade thyroid carcinoma involving both thyroid lobes, with visible tumor necrosis, more than five mitoses per two square millimeters, and multifocal vascular invasion, meaning cancer cells had invaded blood vessels at multiple sites, a well-established risk factor for distant metastasis. Importantly, the surgical margins were negative, and there was no extrathyroidal extension, meaning the tumor had not grown through the thyroid capsule into surrounding neck structures. Lymph node analysis revealed metastatic disease in seven of thirteen central nodes and three of six right lateral nodes, resulting in a pathological stage of pT3a pN1b.

What happened next illustrates both the promise and the limitations of radioactive iodine therapy, the hallmark systemic treatment for differentiated thyroid cancer. Radioactive iodine exploits a unique property of thyroid cells: their ability to actively transport iodine through the sodium-iodide symporter. When differentiated thyroid cancer cells retain this transporter, they can be selectively irradiated from within by ingested radioactive iodine, a treatment with comparatively few side effects because non-thyroid tissues absorb little of the isotope. A diagnostic scan performed in September 2024 demonstrated that the patient’s mediastinal and pulmonary metastases were iodine-avid, meaning the lung and chest deposits visibly concentrated the radioactive tracer. This finding classified her disease as distant metastatic disease, designated cM1, but also offered genuine hope, because iodine-avid metastases are typically considered candidates for effective radioiodine ablation.

Two courses of radioactive iodine treatment were documented. Initial follow-up appeared encouraging: imaging in March 2025 showed improvement in the pulmonary metastases, and the treatment team had reason to believe the iodine-avid disease was responding. However, the trajectory shifted over the following months. By June 2025, the patient’s serum thyroglobulin, a protein produced almost exclusively by thyroid tissue and widely used as a tumor marker for differentiated thyroid cancer after thyroidectomy, had climbed to 656.85 nanograms per milliliter, a level far above the near-undetectable values expected in disease-free patients. In September 2025, pulmonary computed tomography revealed mixed changes, with some lesions improving while others progressed or evolved, and thyroglobulin remained above 500 nanograms per milliliter, confirming that substantial metabolically active thyroid cancer tissue persisted despite therapy.

The reporting authors are appropriately careful about what these findings do and do not prove. Because the exact administered radioactive iodine activities were missing from the record and the imaging and biochemical tests were not fully synchronized in time, the case cannot be definitively classified as radioactive iodine-refractory disease, the formal designation for tumors that either never take up iodine or progress after appropriate radioiodine treatment. This distinction matters enormously for clinical decision-making, since refractory disease opens the door to kinase inhibitors and other targeted therapies, while iodine-avid disease generally argues for repeated radioiodine courses. The authors also note a subtle but important point of precision: the frequently cited 13-centimeter figure describes the clinical mass measured in the neck, not the diameter of a single pathological tumor specimen, a reminder that careful measurement conventions matter when comparing cases across the literature.

Longitudinal evidence on giant thyroid tumors treated with radioactive iodine remains limited, which is precisely why this case report includes a focused review of the existing literature. Most large series of differentiated high-grade thyroid carcinoma emphasize its intermediate position on the aggressiveness spectrum: distinctly worse than conventional papillary and follicular carcinoma, yet generally less explosive than poorly differentiated carcinoma or anaplastic thyroid carcinoma, the almost uniformly fatal undifferentiated form. Differentiated high-grade tumors carry elevated rates of recurrence and distant metastasis, and the presence of necrosis and high mitotic activity has been linked to poorer disease-specific survival in multiple studies. This case adds a valuable data point by documenting the full arc from giant untreated primary tumor through surgery, radioiodine response, and eventual biochemical and radiographic progression over roughly two years of follow-up.

At last contact on August 26, 2026, the patient was alive and reported generalized pain and low-back pain, symptoms that raise the specter of skeletal metastasis, a common distant site for aggressive thyroid cancer, although no imaging confirmation of new metastases was available at the time of the report. Her course delivers several sobering lessons for clinicians and patients alike. First, differentiated appearance on the microscope does not guarantee indolent behavior once necrosis and brisk mitotic activity are present, so the 2022 WHO criteria deserve active application in every thyroid pathology report. Second, early post-treatment improvement after radioactive iodine does not establish durable control, and biochemical surveillance with thyroglobulin remains indispensable for catching treatment failure. Third, slowly enlarging neck masses deserve evaluation long before they become symptomatic, because a six-year delay transformed a potentially straightforward thyroidectomy into a major oncological operation with distant disease already established. As differentiated high-grade thyroid carcinoma becomes more widely recognized, cases like this one will help define its natural history and sharpen the decisions that follow.

Subject of Research: Differentiated high-grade thyroid carcinoma presenting as a giant neck mass with iodine-avid pulmonary metastases

Article Title: Diffuse bilateral differentiated high-grade thyroid carcinoma presenting as a giant clinical neck mass with iodine-avid pulmonary metastases: a case report and focused literature review

Article References: Gao, S., Xu, X., & Wei, W. (2026). Diffuse bilateral differentiated high-grade thyroid carcinoma presenting as a giant clinical neck mass with iodine-avid pulmonary metastases: a case report and focused literature review. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02559-6

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02559-6

Keywords: differentiated high-grade thyroid carcinoma, thyroid cancer, giant neck mass, pulmonary metastasis, radioactive iodine, total thyroidectomy, thyroglobulin, WHO classification 2022, case report, lymph node metastasis, endocrine cancer, BMC Endocrine Disorders